Status:
COMPLETED
Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma
Lead Sponsor:
Agios Pharmaceuticals, Inc.
Conditions:
Advanced Solid Tumors
Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to identify subjects with advanced solid tumors or lymphoma in which the methylthioadenosine phosphorylase (MTAP) protein has been lost.
Detailed Description
Study AG270-PS-001 is a pre-screening study to identify subjects with advanced solid tumors or lymphoma in which the MTAP protein has been lost. Subjects whose tumor tissue has lost the MTAP protein m...
Eligibility Criteria
Inclusion
- Be ≥18 years of age.
- Have a histologically confirmed diagnosis of an advanced solid tumor (other than a primary CNS malignancy) or lymphoma.
- Have archival tumor tissue that can be provided for assessment of MTAP deletion status.
- Have given written informed consent to participate in this study.
Exclusion
- Have a primary CNS malignancy (eg, GBM).
- Have a medical or psychological condition deemed by the Investigator likely to interfere with the subject's ability to give informed consent or participate in the study.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2019
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT03361358
Start Date
March 1 2018
End Date
September 30 2019
Last Update
March 16 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston, MA
Boston, Massachusetts, United States, 02114
2
Nashville, TN
Nashville, Tennessee, United States, 37203
3
Barcelona, Spain
Barcelona, Spain, 08035